Single biomarkers can only go so far in predicting responses given the complexity and heterogeneity of individual malignancies and their microenvironments.
The precision of the targeted methylation sequencing assay for localizing the cancer tissue of origin was reported to be 89%.
Nearly 11% of patients in the study who underwent immune checkpoint inhibition for NSCLC experienced HPD.
Some oncologic driver mutations may be missed when NGS is performed using either tumor tissue or tumor circulating cell-free DNA alone.
There is great interest in evaluating the link between hypercalcemia and prognosis in ccRCC by researching the genes that influence calcium levels.
Although historically, the 5-year OS rate for patients with advanced NSCLC treated with chemotherapy is less than 5%, patients treated with nivolumab had a 5-year OS of 13.4%.
Preclinical studies performed in cell line and mouse models of lung adenocarcinoma showed that mesothelin-directed CAR-T was effective and not associated with toxicity.
OS was significantly higher in the subgroup of patients with high tumor expression of PD-L1 who received atezolizumab plus chemotherapy compared with chemotherapy alone.
Continued molecular stratification in lung cancer appears imminent, and many of the patients in these genetic subgroups may benefit from the use of targeted therapies.
Fewer than 2% of the people in the LIBRETTO-001 study discontinued treatment with selpercatinib due to treatment-related adverse events.
